Phenanthroline derivatives
US6200974A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 4, 1999 |
| Grant date | Mar 13, 2001 |
| Priority date | — |
| Expiry date | May 4, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4745
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a phenanthroline derivative of formula (I) ##STR1## wherein, for example, PA1 R.sup.1 is hydrogen, carboxy, cyano, nitro, (1-4C)alkyl, (1-6C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkanoyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl; PA1 R.sup.2 is, for example, hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl or N,N-[di-(1-4C)alkyl]thiocarbamoyl; PA1 R.sup.3 and R.sup.4, which may be the same or different, are, for example, hydrogen or halo; and PA1 R.sup.5 is, for example, hydrogen, di-(1-4C)alkylamino or halo; or a pharmaceutically-acceptable salt thereof. The invention further provides pharmaceutical compositions comprising phenanthroline derivatives, processes for making the same and their use in producing an anti-fibroproliferative effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.